- Home
- PIII vs PRPO Comparison
PIII vs PRPO Comparison
Compare PIII & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- PRPO
- Stock Information
- Founded
- PIII 2015
- PRPO N/A
- Country
- PIII United States
- PRPO United States
- Employees
- PIII N/A
- PRPO N/A
- Industry
- PIII Medical/Nursing Services
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- PIII Health Care
- PRPO Industrials
- Exchange
- PIII Nasdaq
- PRPO Nasdaq
- Market Cap
- PIII 27.8M
- PRPO 30.2M
- IPO Year
- PIII N/A
- PRPO N/A
- Fundamental
- Price
- PIII $9.22
- PRPO $21.42
- Analyst Decision
- PIII Strong Buy
- PRPO
- Analyst Count
- PIII 3
- PRPO 0
- Target Price
- PIII $17.50
- PRPO N/A
- AVG Volume (30 Days)
- PIII 5.1K
- PRPO 15.6K
- Earning Date
- PIII 11-11-2025
- PRPO 11-05-2025
- Dividend Yield
- PIII N/A
- PRPO N/A
- EPS Growth
- PIII N/A
- PRPO N/A
- EPS
- PIII N/A
- PRPO N/A
- Revenue
- PIII $1,461,823,000.00
- PRPO $21,242,000.00
- Revenue This Year
- PIII N/A
- PRPO N/A
- Revenue Next Year
- PIII $10.45
- PRPO N/A
- P/E Ratio
- PIII N/A
- PRPO N/A
- Revenue Growth
- PIII 4.20
- PRPO 27.05
- 52 Week Low
- PIII $5.80
- PRPO $3.90
- 52 Week High
- PIII $24.73
- PRPO $22.38
- Technical
- Relative Strength Index (RSI)
- PIII 54.75
- PRPO 63.26
- Support Level
- PIII $8.65
- PRPO $16.40
- Resistance Level
- PIII $9.29
- PRPO $19.00
- Average True Range (ATR)
- PIII 0.40
- PRPO 1.47
- MACD
- PIII -0.03
- PRPO -0.06
- Stochastic Oscillator
- PIII 76.24
- PRPO 92.43
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.